PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35568074-5	2022	Further study showed that Anlotinib-induced PD-L1 expression was regulated by autocrine IL-6 mediated JAK2/STAT3 signaling pathways.	anlotinib	26-35	signal transducer and activator of transcription 3	Homo sapiens	107-112	
34997858-0	2022	Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway.	anlotinib	0-9	signal transducer and activator of transcription 3	Homo sapiens	90-95	
34997858-13	2022	Mechanistically, anlotinib inhibited the Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3)/VEGFA signaling pathway.	anlotinib	17-26	signal transducer and activator of transcription 3	Homo sapiens	63-113	
34997858-13	2022	Mechanistically, anlotinib inhibited the Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3)/VEGFA signaling pathway.	anlotinib	17-26	signal transducer and activator of transcription 3	Homo sapiens	115-120	
34997858-16	2022	Finally, anlotinib inhibited tumor growth and JAK2/STAT3/VEGFA signaling in xenografts.	anlotinib	9-18	signal transducer and activator of transcription 3	Homo sapiens	51-56	
34997858-17	2022	CONCLUSION: Anlotinib exerts anti-glioblastoma activity possibly through the JAK2/STAT3/VEGFA signaling pathway.	anlotinib	12-21	signal transducer and activator of transcription 3	Homo sapiens	82-87	
33755971-0	2021	Anlotinib inhibits the progress of colorectal cancer cells by antagonizing VEGFR/JAK2/STAT3 axis.	anlotinib	0-9	signal transducer and activator of transcription 3	Homo sapiens	86-91	
33755971-11	2021	Furthermore, we found that anlotinib inhibiting the phosphorylation level of VEGFR, Janus Kinase 2 (JAK2), and Signal Transducer and Activator of Transcription 3 (STAT3).	anlotinib	27-36	signal transducer and activator of transcription 3	Homo sapiens	111-161	
33755971-11	2021	Furthermore, we found that anlotinib inhibiting the phosphorylation level of VEGFR, Janus Kinase 2 (JAK2), and Signal Transducer and Activator of Transcription 3 (STAT3).	anlotinib	27-36	signal transducer and activator of transcription 3	Homo sapiens	163-168	
33755971-13	2021	CONCLUSIONS: These findings suggested that anlotinib might benefit colorectal cancer therapy by antagonizing VEGFR/JAK2/STAT3 signaling.	anlotinib	43-52	signal transducer and activator of transcription 3	Homo sapiens	120-125	
30755242-0	2019	Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells.	anlotinib	87-96	signal transducer and activator of transcription 3	Homo sapiens	110-115	
30755242-14	2019	Further in vivo studies showed that anlotinib inhibited tumor growth, induced autophagy and suppressed JAK2/STAT3/VEGFA pathway, and CQ enhanced this effect.	anlotinib	36-45	signal transducer and activator of transcription 3	Homo sapiens	108-113	
30755242-16	2019	Autophagy inhibition further enhanced the cytotoxic effects of anlotinib, and potentiated the anti-angiogenic property of anlotinib through JAK2/STAT3/VEGFA signaling.	anlotinib	122-131	signal transducer and activator of transcription 3	Homo sapiens	145-150